Start care with our licensed providers today
There is an increasing focus on the potential contributory mechanistic role of the gut microbiota in the metabolic effects of glucoregulatory and weight loss promoting drugs, including glucagon-like peptide-1 (GLP-1) receptor agonists, which have become well-established therapies in type 2 diabetes and obesity 16,17
cancel before your next renewal
Risk factors include the speed and magnitude of weight loss, pre-existing nutritional deficiencies, age, sex (women are more commonly affected), and individual genetic susceptibility
TIPS TO REDUCE SIDE EFFECTS BOOK NOW Start Low, Go Slow: Gradually increase your dosage to minimize potential side effects
[PMID: 2883900] PubMed record related to this compound for laboratory literature review